Agalsidase Beta
CAS 335543-79-2Biologic
Overview
Agalsidase beta is a recombinant form of alpha-galactosidase A used as enzyme replacement therapy in the treatment of Fabry disease, a genetic disorder resulting from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. The enzyme facilitates the breakdown of this fat, relieving some of the symptoms associated with the disorder.
Therapeutic areas
Genetic DisordersMetabolic Disorders
Verified Supplier Partner
Do you supply Agalsidase Beta? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.